KPTI

7.95

4.67% -0.40

Handel nachbörslich: 7.95

Karyopharm Therapeutics Inc (KPTI)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.35

Offen:

$8.7

24-Stunden-Volumen:

120.74K

Relative Volume:

1.60

Marktkapitalisierung:

$70.27M

Einnahmen:

$140.46M

Nettoeinkommen (Verlust:

$-146.34M

KGV:

-6.2598

EPS:

-1.27

Netto-Cashflow:

$-117.73M

1W Leistung:

-11.32%

1M Leistung:

-22.19%

6M Leistung:

-32.14%

1J Leistung:

-60.10%

1-Tages-Spanne:

$7.885

$8.70

1-Wochen-Bereich:

$7.611

$10.38

52-Wochen-Spanne:

$7.611

$25.50

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Firmenname

Karyopharm Therapeutics Inc

Sektor

Healthcare (1189)

Branche

Biotechnology (675)

Telefon

617-658-0600

Adresse

85 WELLS AVENUE, NEWTON, MA

Mitarbeiter

279

Twitter

@Karyopharm

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

KPTI's Discussions on Twitter

Vergleichen Sie KPTI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KPTI Karyopharm Therapeutics Inc	7.95	70.27M	140.46M	-146.34M	-117.73M	-1.27
VRTX Vertex Pharmaceuticals Inc	479.79	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.74	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.67	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.75	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	271.80	29.71B	3.32B	-860.46M	-1.04B	-8.32

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-01-19	Eingeleitet	Piper Sandler	Overweight
2022-11-04	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2022-02-09	Hochstufung	JP Morgan	Underweight → Neutral
2021-11-19	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-08-06	Herabstufung	JP Morgan	Overweight → Neutral
2021-08-06	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-08-06	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-07-02	Eingeleitet	Morgan Stanley	Overweight
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-17	Herabstufung	Wedbush	Outperform → Neutral
2019-07-23	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-05	Bestätigt	H.C. Wainwright	Buy
2019-07-05	Bestätigt	Robert W. Baird	Outperform
2019-03-01	Herabstufung	JP Morgan	Overweight → Neutral
2019-02-28	Bestätigt	BofA/Merrill	Underperform
2019-02-27	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-01-03	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-12-03	Eingeleitet	B. Riley FBR	Buy
2018-11-09	Hochstufung	Wedbush	Neutral → Outperform
2018-05-24	Herabstufung	Wedbush	Outperform → Neutral
2018-04-02	Fortgesetzt	Leerink Partners	Outperform
2017-11-15	Fortgesetzt	H.C. Wainwright	Buy
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2016-09-08	Bestätigt	H.C. Wainwright	Buy
2016-08-30	Hochstufung	Jefferies	Hold → Buy
2016-08-18	Eingeleitet	H.C. Wainwright	Buy
2016-06-28	Eingeleitet	Robert W. Baird	Outperform

Alle ansehen

Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten

Feb 27, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 26, 2025

Karyopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal year - Investing.com

Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025

Can Karyopharm's 15:1 Reverse Split Save Its Nasdaq Listing? - StockTitan

Feb 24, 2025

Karyopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Feb 24, 2025

Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025

Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025

Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025

Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 20, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target - Investing.com India

Feb 20, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 20, 2025

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Feb 20, 2025